Life Science Trends, presented by Chris Hite on Financing Panel

Life Science Trends February 2012Strictly Private and Confidential

Within Healthcare, Slowing Revenue Outlook For Nearly Every Subsector (1) Change in CAGR 22% Generics 19% - 20% Managed Care 5% - 19% Healthcare IT 25% + 18% CROs 4% - 17% Biotech 8% - 16% MedTech 6% - 14%Specialty Pharma 16% + 12% Supply Chain 8% - 11% Facilities 8% - 7%Life Science Tools 4% - 5% Major Pharma 1% - 0% 5% 10% 15% 20% 25% 30% 2004-2008 Revenue CAGR 2008-2012 Revenue CAGR 1 Source: Wall Street Research. (1) Represents growth trend when comparing periods 2004-2008 to 2008-2012.

Declining R&D ProductivityNME approval peaked in the mid 1990’s, followed by a period of decline starting around 2000; while R&Dspend continued to grow. $50 60 45 In du stry R & D S pe nd ( $ bn ) 50 40 35 F D A N M E A pp ro va ls 40 30 25 30 20 20 15 (1) 10 10 5 0 0 1970 1975 1980 1985 1990 1995 2000 2005 Number of FDA NME Approvals2 Source: Rodney Zenmmel, PhD., McKinsey & Company, FDA, PhRMA. (1) Includes NCEs and BLAs. BLAs included 1986 onward; biologic approvals in prior years assumed negligible.

Life Science IPOs Since 2003The financial crisis clearly impacted the biotech IPO market as volumes are off significantly over the pastfew years. Valuations continue to be challenged as does the short term aftermarket performance. # of Biotech IPOs Per Year Since 2003 Average Performance Offer + 30 Days 8.8% 7.3% 21 19 0.1% N/A 0.8% N/A 14 (5.5%) (4.0%) 10 (9.1%) 9 7 6 1 1 0 (31.5%) 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012Source: Dealogic. Excludes offerings < $25 mm in proceeds. Source: Dealogic. Excludes offerings < $25 mm in proceeds. Average Market Cap At Pricing Over Last Ten Years Average Offering Size Over Last Ten Years $273 $279 $278 $285 $260 $78 $72 $65 $66 $68 $65 $213 $207 $62 $202 $55 $52 $157 N/A N/A 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012Source: Dealogic. Excludes offerings < $25 mm in proceeds. Source: Dealogic. Excludes offerings < $25 mm in proceeds.3

Life Science IPOs (Cont’d)The majority of IPOs continue to be priced below the marketing ranges, with particular valuation sensitivityexperienced over the past 2 years. Later stage assets are dominating the IPO landscape currently. Above / Below / Within Range Average File-to-Offer (%) Per Year 10% 10% 5% 14% N/A N/A 16% 19% 36% (8%) (9%) 40% (14%) 100% 100% 100% 100% (19%) 79% 86% 71% 64% (27%) (27%) 50% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 (43%) (46%) Below Within Range Above 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012Source: Dealogic. Excludes offerings < $25 mm in proceeds. Source: Dealogic. Excludes offerings < $25 mm in proceeds. Clinical Stage at IPO Since 2003 NBI Annual Performance Over Last Ten Years 46% 1 5 12 2 16% 15% 5 12% 1 5 6% 5% 1 3% 4 1 1% 6 2 9 6 8 6 6 2 3 1 1 1 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 (13%) 2003 2004 2005 2006 2007 2008 2009 2010 2011 I or Pre-Clinical II III or NDA Filed CommercialSource: SEC filings. Source: Factset.4

Life Science FOs Since 2003Although the biotech follow-on market has experienced strong volume, deal size has declined in recentyears as has the market cap of the average issuer. Follow-ons have tended to perform well in aftermarket. # of Biotech Follow-Ons Per Year Since 2003 Average Performance Offer + 30 Days 17.7% 49 49 45 43 42 40 36 33 8.6% 5.6% 6.1% 14 4.3% 4.4% 3.9% 7 2.2% 2.6% N/A 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012Source: Dealogic. Excludes offerings < $25 mm in proceeds. Source: Dealogic. Excludes offerings < $25 mm in proceeds. Average Market Cap At Pricing Over Last Ten Years Average Offering Size Over Last Ten Years $1852 $156 $154 $158 $1466 $1500 $130 $94 $94 $95 $94 $837 $879 $74 $582 $641 $610 $60 $559 $353 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012Source: Dealogic. Excludes offerings < $25 mm in proceeds. Source: Dealogic. Excludes offerings < $25 mm in proceeds.5

Life Science M&A Transactions: 2007 – 2012 YTDM&A over the past 5 years highlighted important trends, including pharma’s need for greater access toantibody platforms, larger biopharmas buying their partners, and pharma’s need for enhanced pipelines.Public and Private Life Science Acquisitions, 2007-2012 YTD(total transaction value in billions of USD, # of transactions) $300 40 35 250 $228 8 30Transaction Value ($bn) 200 25 # Transactions 150 20 220 15 100 $83 $71 10 11 31 $48 $47 50 2 12 5 59 52 36 45 0 0 - 2007 - 2008 - 2009 - 2010 2011-- YTD Public Acquisitions Private Acquisitions Total # Acquisitions # Public Acquisitions # Private Acquisitions6 Source: MergerMarket, EvaluatePharma, Company information. Note: Public and Private transaction values include earn-outs and CVRs.

Private Biotech M&A Transactions Private biotech M&A transactions have increasingly been structured with significant earn-out components. The earn-out components have been reaching up to 50% or more of the total deal value. ($ in millions) 2011 Avg: $335mm (1) 2010 Avg: $128mm (1) 2009 Avg: $193mm (1) 2008 Avg: $161mm (1) 2007 Avg: $279mm (1) 2006 Avg: $339mm (1)$1,000 $ 1,080 $ 1,000 1,000 $935 $900 (2) 900 $ 130 $851 $470 $800 800 $ 700 $ 575 700 $ 75 $ 640 $ 620 $600 $594 600 $560 $537 $575 $ 528 $537 $525 $ 500 $ 515 $100 $500 $500 $500 500 $475 $ 225 $ 461 $300 $454 $425 $ 150 $430 $420 $ 900 $ 403 $ 400$ 400 $ 400 $ 390 $250 $ 380 $ 380 400 $805 $ 150 $75 $366 $ 300 $ 250 $350 $ 25 $ 338 $500 $ 325 $ 315 $ 310 $ 300 $400 $ 300 $300 $ 90 $ 625 $485 $ 292 300 $ 610 $ 275 $305 $415 $263 $255 $200 $250 $225 $ 235 $168 $120 $500 $ 310 $300 $494 $500 $ 250 $454 Baxter / Prism Richter / PregLem P Alexion/ Enobia Daiichi / Plexxikon Valeant / iNova Gilead / Calistoga ira Takeda/ Intellikine Salix / Oceana Biotie/ Synosia Alexion/ Taligen a Sanofi / TargeGen Roche/ Marcadia Eli Lilly / Alnara Cadence/ Incline Novartis / Corthera Sanofi / Fovea Cubist / Calixa Cephalon/ Ception a gen/ Ilypsa Merck / NovaCardia ypnion Forest / Cerexa gen/ Avidia a AZN / Arrow gen/ BioVex Pfizer / FoldRx artCells Actelion/ Trophos Onyx / Proteolix Eisai / akaRx uxley is Novartis / Protez Teva/ CoGenesys Wyeth/ Thiakis Biovail / Prestwick Astellas / Agensys BMS/ Adnexus Eisai / Morphotek MGI / AkaRx gen/ Alantos antis Gilead / Corus ion/ Cabrellis Gilead / CGI Cephalon/ Gem X Gilead / Arresto BioMarin/ Lead ed BioMarin/ ZyStor Celgene/ Gloucester Sanofi / BiPar $425 AstraZeneca/ Novexel $430 $420 Merck / GlycoFi Allergan/ Vicept Pfizer / Rinat Lilly / Avid Radiopharm Daiichi / U3 Pharm BiogenIdec / Conform 200 $ 175 Roche/ TH Boehringer Ingelheim/ Actim $ 400 $ 400 $ 100 in Roche/ Piram $387 BMS/ Am $375 $ 150 $366 $150 $ 365 $ 200 $ 340 $350 $ 325 $ 315$255 $300 GSK/ Dom $ 15 BioMarin/ H $325 $ 300 $ 121 $ 111 $300 $285 $ 250 $120 $115 Lilly / H $287 $ 290 $ 97 $276 Merck / Sm $250 $255 $ 235 $100 $ 100 $225 $225 100 Am $ 170 $ 190 Am $ 180 $ 59 $ 160$120 $150 $57 Am Am $ 156 $150 $ 45 Pharm $ 121 $ 111 $ 120 $93 $79 $ 120 $ 128 $75 $ 75 $93 $100 $44 $ 100$ 100 $100 $30 $45 $57 $55 0 $ 7 $13 $0 $ 22 $ 18 $ 15 Total transaction ($inmillions) value Max $1,080 Milestones Upfront Min $57 Average $408 Median $390 Note: Values includemilestones Source: Company Press Releases and VentureSource. 7 (1) Average upfront payments. (2) Upfront not disclosed.

Life Science M&A Transactions: 2007 – 2011The key theme throughout this period has been a focus on late stage development assets and marketedproducts. 62% of public acquisition targets belonged to this category.Public and Private Life Science Acquisitions, by Phase, 2007-2011(# transactions) 16 15 14 14 13 12 3 10 7 10 9 1 9 9 8 8 15 3 7 6 6 5 5 5 7 5 8 10 9 7 4 2 2 5 3 7 3 3 7 6 5 2 2 2 2 1 1 3 3 3 2 2 2 1 1 1 1 1 1 0 I II III Mkt I II III Mkt I II III Mkt I II III Mkt I II III Mkt 2007 2008 2009 2010 2011 $48bn $47bn $228bn $71bn $75bn Public companies Private companies8 Source: MergerMarket, EvaluatePharma, Company information.

Life Science Landscape ($2bn to $20bn) 33% of the public Life Science companies illustrated below (in 2007) have been acquired over the past 5 years. The number of attractive Life Science assets continues to decline. Biopharma Companies with Market Cap Between $2bn to $20bn – 5 Years Ago ($ in billions) $20 $17.5 $16.8 $15.9 15 $12.1 $10.9 10 $8.2 $6.8 $6.4 $5.8 - Acquired $5.4 $5.0 $4.9 $4.8 $4.5 $4.3 $4.3 5 $3.9 $3.9 $3.8 $3.6 $3.4 $3.3 $2.7 $2.5 $2.5 $2.1 $2.0 $2.0 0 Biopharma Companies with Market Cap Between $2bn to $20bn – Today ($ in billions) $20 $18.6 $15.1 $14.6 15 $9.6 10 $8.8 $8.5 $8.2 $7.7 $7.4 $7.4 $5.2 5 $4.3 $4.3 $4.2 $3.9 $2.9 $2.7 $2.7 $2.6 $2.6 $2.5 $2.5 $2.4 $2.4 $2.3 $2.2 $2.2 $2.2 0Inc / Dec 71% 337% 941% 123% 572% (46%) 29% 71% (39%) 174% 8% 184% 12% 26% (33%) 138% 416% 520% 174% 565% (49%) 82% (37%) 608% 2,256% 732% 340% 110%Since 2007 9 Source: FactSet, Wall Street research, Company filings. Note: Market data as of 2/3/2007 and 2/3/2012.

IRS Circular 230 Disclosure: Citigroup Inc. and its affiliates do not provide tax or legal advice. Any discussion of tax matters in these materials (i) is not intended or written to be used, and cannot beused or relied upon, by you for the purpose of avoiding any tax penalties and (ii) may have been written in connection with the "promotion or marketing" of any transaction contemplated hereby("Transaction"). Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.Any terms set forth herein are intended for discussion purposes only and are subject to the final terms as set forth in separate definitive written agreements. This presentation is not a commitment to lend, syndicate afinancing, underwrite or purchase securities, or commit capital nor does it obligate us to enter into such a commitment, nor are we acting as a fiduciary to you. By accepting this presentation, subject to applicable lawor regulation, you agree to keep confidential the information contained herein and the existence of and proposed terms for any Transaction.Prior to entering into any Transaction, you should determine, without reliance upon us or our affiliates, the economic risks and merits (and independently determine that you are able to assume these risks) as well asthe legal, tax and accounting characterizations and consequences of any such Transaction. In this regard, by accepting this presentation, you acknowledge that (a) we are not in the business of providing (and youare not relying on us for) legal, tax or accounting advice, (b) there may be legal, tax or accounting risks associated with any Transaction, (c) you should receive (and rely on) separate and qualified legal, tax andaccounting advice and (d) you should apprise senior management in your organization as to such legal, tax and accounting advice (and any risks associated with any Transaction) and our disclaimer as to thesematters. By acceptance of these materials, you and we hereby agree that from the commencement of discussions with respect to any Transaction, and notwithstanding any other provision in this presentation, wehereby confirm that no participant in any Transaction shall be limited from disclosing the U.S. tax treatment or U.S. tax structure of such Transaction.We are required to obtain, verify and record certain information that identifies each entity that enters into a formal business relationship with us. We will ask for your complete name, street address, and taxpayer IDnumber. We may also request corporate formation documents, or other forms of identification, to verify information provided.Any prices or levels contained herein are preliminary and indicative only and do not represent bids or offers. These indications are provided solely for your information and consideration, are subject to change at anytime without notice and are not intended as a solicitation with respect to the purchase or sale of any instrument. The information contained in this presentation may include results of analyses from a quantitativemodel which represent potential future events that may or may not be realized, and is not a complete analysis of every material fact representing any product. Any estimates included herein constitute our judgmentas of the date hereof and are subject to change without any notice. We and/or our affiliates may make a market in these instruments for our customers and for our own account. Accordingly, we may have a positionin any such instrument at any time.Although this material may contain publicly available information about Citi corporate bond research, fixed income strategy or economic and market analysis, Citi policy (i) prohibits employees from offering, directly orindirectly, a favorable or negative research opinion or offering to change an opinion as consideration or inducement for the receipt of business or for compensation; and (ii) prohibits analysts from being compensatedfor specific recommendations or views contained in research reports. So as to reduce the potential for conflicts of interest, as well as to reduce any appearance of conflicts of interest, Citi has enacted policies andprocedures designed to limit communications between its investment banking and research personnel to specifically prescribed circumstances.© 2012 Citigroup Global Markets Inc. Member SIPC. All rights reserved. Citi and Citi and Arc Design are trademarks and service marks of Citigroup Inc. or its affiliates and are used and registered throughoutthe world.Citi believes that sustainability is good business practice. We work closely with our clients, peer financial institutions, NGOs and other partners to finance solutions to climate change, develop industry standards,reduce our own environmental footprint, and engage with stakeholders to advance shared learning and solutions. Highlights of Citi’s unique role in promoting sustainability include: (a) releasing in 2007 a ClimateChange Position Statement, the first US financial institution to do so; (b) targeting $50 billion over 10 years to address global climate change: includes significant increases in investment and financing of renewableenergy, clean technology, and other carbon-emission reduction activities; (c) committing to an absolute reduction in GHG emissions of all Citi owned and leased properties around the world by 10% by 2011;(d) purchasing more than 234,000 MWh of carbon neutral power for our operations over the last three years; (e) establishing in 2008 the Carbon Principles; a framework for banks and their U.S. power clients toevaluate and address carbon risks in the financing of electric power projects; (f) producing equity research related to climate issues that helps to inform investors on risks and opportunities associated with the issue;and (g) engaging with a broad range of stakeholders on the issue of climate change to help advance understanding and solutions.Citi works with its clients in greenhouse gas intensive industries to evaluate emerging risks from climate change and, where appropriate, to mitigate those risks. efficiency, renewable energy & mitigation

Life Science Trends, presented by Chris Hite on Financing Panel

by CEDPrograms on Feb 20, 2012

Accessibility

Categories

Upload Details

Usage Rights

1 Embed 22

Statistics

Life Science Trends, presented by Chris Hite on Financing Panel Presentation Transcript